164 related articles for article (PubMed ID: 18177726)
1. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Addy C; Wright H; Van Laere K; Gantz I; Erondu N; Musser BJ; Lu K; Yuan J; Sanabria-Bohórquez SM; Stoch A; Stevens C; Fong TM; De Lepeleire I; Cilissen C; Cote J; Rosko K; Gendrano IN; Nguyen AM; Gumbiner B; Rothenberg P; de Hoon J; Bormans G; Depré M; Eng WS; Ravussin E; Klein S; Blundell J; Herman GA; Burns HD; Hargreaves RJ; Wagner J; Gottesdiener K; Amatruda JM; Heymsfield SB
Cell Metab; 2008 Jan; 7(1):68-78. PubMed ID: 18177726
[TBL] [Abstract][Full Text] [Related]
2. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
[TBL] [Abstract][Full Text] [Related]
4. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Hagmann WK
Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
[TBL] [Abstract][Full Text] [Related]
5. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study.
Proietto J; Rissanen A; Harp JB; Erondu N; Yu Q; Suryawanshi S; Jones ME; Johnson-Levonas AO; Heymsfield SB; Kaufman KD; Amatruda JM
Int J Obes (Lond); 2010 Aug; 34(8):1243-54. PubMed ID: 20212496
[TBL] [Abstract][Full Text] [Related]
6. Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Lin LS; Ha S; Ball RG; Tsou NN; Castonguay LA; Doss GA; Fong TM; Shen CP; Xiao JC; Goulet MT; Hagmann WK
J Med Chem; 2008 Apr; 51(7):2108-14. PubMed ID: 18333607
[TBL] [Abstract][Full Text] [Related]
7. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes.
Kipnes MS; Hollander P; Fujioka K; Gantz I; Seck T; Erondu N; Shentu Y; Lu K; Suryawanshi S; Chou M; Johnson-Levonas AO; Heymsfield SB; Shapiro D; Kaufman KD; Amatruda JM
Diabetes Obes Metab; 2010 Jun; 12(6):517-31. PubMed ID: 20518807
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
Aronne LJ; Tonstad S; Moreno M; Gantz I; Erondu N; Suryawanshi S; Molony C; Sieberts S; Nayee J; Meehan AG; Shapiro D; Heymsfield SB; Kaufman KD; Amatruda JM
Int J Obes (Lond); 2010 May; 34(5):919-35. PubMed ID: 20157323
[TBL] [Abstract][Full Text] [Related]
9. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Addy C; Rothenberg P; Li S; Majumdar A; Agrawal N; Li H; Zhong L; Yuan J; Maes A; Dunbar S; Cote J; Rosko K; Van Dyck K; De Lepeleire I; de Hoon J; Van Hecken A; Depré M; Knops A; Gottesdiener K; Stoch A; Wagner J
J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950
[TBL] [Abstract][Full Text] [Related]
10. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
Du W; Jewell JP; Lin LS; Colandrea VJ; Xiao JC; Lao J; Shen CP; Bateman TJ; Reddy VB; Ha SN; Shah SK; Fong TM; Hale JJ; Hagmann WK
Bioorg Med Chem Lett; 2009 Sep; 19(17):5195-9. PubMed ID: 19632830
[TBL] [Abstract][Full Text] [Related]
12. A critical review of the cannabinoid receptor as a drug target for obesity management.
Akbas F; Gasteyger C; Sjödin A; Astrup A; Larsen TM
Obes Rev; 2009 Jan; 10(1):58-67. PubMed ID: 18721231
[TBL] [Abstract][Full Text] [Related]
13. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice.
Fichna J; Sibaev A; Sałaga M; Sobczak M; Storr M
Neurogastroenterol Motil; 2013 Aug; 25(8):e550-9. PubMed ID: 23692073
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans.
Fogteloo AJ; Pijl H; Frölich M; McCamish M; Meinders AE
Diabetes Nutr Metab; 2003 Apr; 16(2):109-14. PubMed ID: 12846450
[TBL] [Abstract][Full Text] [Related]
15. Taranabant, a novel cannabinoid type 1 receptor inverse agonist.
Fremming BA; Boyd ST
Curr Opin Investig Drugs; 2008 Oct; 9(10):1116-29. PubMed ID: 18821475
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.
Fong TM; Heymsfield SB
Int J Obes (Lond); 2009 Sep; 33(9):947-55. PubMed ID: 19597516
[TBL] [Abstract][Full Text] [Related]
17. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
Schoedel KA; Addy C; Chakraborty B; Rosko K; Dunbar S; Maes A; Chen N; Stoch SA; Wagner J; Chodakewitz J; Sellers EM
J Clin Psychopharmacol; 2012 Aug; 32(4):492-502. PubMed ID: 22722508
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
Addy C; Jumes P; Rosko K; Li S; Li H; Maes A; Johnson-Levonas AO; Chodakewitz J; Stoch SA; Wagner JA
J Clin Pharmacol; 2009 Oct; 49(10):1228-38. PubMed ID: 19783715
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.
Kopka IE; Lin LS; Jewell JP; Lanza TJ; Fong TM; Shen CP; Lao ZJ; Ha S; Castonguay LG; Van der Ploeg L; Goulet MT; Hagmann WK
Bioorg Med Chem Lett; 2010 Aug; 20(16):4757-61. PubMed ID: 20643546
[TBL] [Abstract][Full Text] [Related]
20. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.
Burns HD; Van Laere K; Sanabria-Bohórquez S; Hamill TG; Bormans G; Eng WS; Gibson R; Ryan C; Connolly B; Patel S; Krause S; Vanko A; Van Hecken A; Dupont P; De Lepeleire I; Rothenberg P; Stoch SA; Cote J; Hagmann WK; Jewell JP; Lin LS; Liu P; Goulet MT; Gottesdiener K; Wagner JA; de Hoon J; Mortelmans L; Fong TM; Hargreaves RJ
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9800-5. PubMed ID: 17535893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
